| Zacks Company Profile for Incyte Corporation (INCY : NSDQ) |
|
|
| |
| • Company Description |
| Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
Number of Employees: 2,617 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $68.94 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,594,325 shares |
| Shares Outstanding: 193.57 (millions) |
| Market Capitalization: $13,344.71 (millions) |
| Beta: 0.68 |
| 52 Week High: $83.95 |
| 52 Week Low: $53.56 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
0.98% |
-4.09% |
| 12 Week |
16.91% |
1.82% |
| Year To Date |
-0.19% |
-6.78% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
1801 AUGUSTINE CUT-OFF
-
WILMINGTON,DE 19803
USA |
ph: 302-498-6700
fax: 302-425-2750 |
ir@incyte.com |
http://www.incyte.com |
|
|
| |
| • General Corporate Information |
Officers
Herve Hoppenot - Chief Executive Officer
Christiana Stamoulis - Chief Financial Officer
Thomas Tray - Vice President
Julian C. Baker - Director
Otis W. Brawley - Director
|
|
Peer Information
Incyte Corporation (CORR.)
Incyte Corporation (RSPI)
Incyte Corporation (CGXP)
Incyte Corporation (BGEN)
Incyte Corporation (GTBP)
Incyte Corporation (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45337C102
SIC: 8731
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
|
|
Share - Related Items
Shares Outstanding: 193.57
Most Recent Split Date: 9.00 (2.00:1)
Beta: 0.68
Market Capitalization: $13,344.71 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $1.29 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $4.75 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 8.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 25.00% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/29/25 |
|
|
|
| |
